Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 894416 in Healthy Japanese Men
NCT04540874Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in asthma comparing BI 894416 25mg with Placebo (2 arms). Primary endpoint: Percentage of Participants With Drug Related Adverse Events up to 17 days. Started Oct 2020; status: terminated.
02
Drugs
BI 894416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04540874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540874.